December 1, 2020

 

Avivagen announces expansion of non-dilutive financing in support of increased product sales

 

 

Avivagen Inc. has announced last month that, given the recent significant ramp up in placed orders for its OxC-beta Livestock™ and the upcoming launch of its human nutraceutical product, it has obtained additional debt financing of $350,000 through an unsecured  Promissory Note from a Canadian financial institution.

 

The financing is in addition to the $500,000 borrowed from the same lender on the same terms in October 2020.

 

The note is payable on demand and bears interest at 12% per annum.

 

The funds will be used to support ongoing general operating activities which include, but are not limited to, the ramp up in inventory in support of increasing frequency and size of orders for OxC-beta Livestock™.

 

- Avivagen

Video >

Follow Us

FacebookTwitterLinkedIn